Global Health Ltd Q3 FY26 Earnings Analysis
Published 5 Jul 2026 | Healthcare Services | Market Cap: ₹37.9K Cr
Price
₹1,425
Market Cap
₹37.9K Cr
P/E Ratio
66.2
How does Global Health Ltd rank in Healthcare Services?
Compare Global Health Ltd against every Healthcare Services company this quarter on revenue, margins and earnings-call signals.
Global Health Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹1.2K Cr, net profit ₹142 Cr.
Full financials →Earnings Summary
Developing hospitals (Lucknow, Patna) are showing strong growth with income up 28% in 9 months (excluding Noida) and margin expansion from 30% to 31.1%. Developing hospitals like Lucknow and Patna are showing strong double-digit revenue and EBITDA growth, with Lucknow margins improving by over 150 bps YoY and stable Patna margins. - Medanta Noida is in ramp-up phase; EBITDA losses are near peak with steady improvement expected, but no specific breakeven guidance provided. - ARPOB growth is expected to moderate to single digits (5%-7% annually) in the next 2-3 years, lower than past double-digit growth. - CAPEX is projected around Rs.
📊 Revenue & Sales Performance
- →Developing hospitals (Lucknow, Patna) are showing strong growth with income up 28% in 9 months (excluding Noida) and margin expansion from 30% to 31.1%.
- →Noida hospital is ramping up as per expectations, with better volume growth since December and plans to add 200 more beds, expected to scale efficiently.
- →Overall inpatient volumes in developing hospitals increased by 27% YoY, with occupancy at 62% and ARPOB rising 8% to Rs.56,853.
- →Brownfield expansions potential includes 496 beds across Lucknow, Patna, and Noida, driving medium-term growth with minimal capex.
- →New specialties and complex work like robotic surgery are being added, contributing to incremental revenue.
- →ARPOB growth expected to be moderate at 5%-7% annually, reflecting stabilized tariff growth.
- →Noida's loss peak may be behind, with revenue run rate improving in recent months, indicating positive future earnings momentum.
📈 Profitability & Margins
- →Developing hospitals like Lucknow and Patna are showing strong double-digit revenue and EBITDA growth, with Lucknow margins improving by over 150 bps YoY and stable Patna margins.
- →Medanta Noida is in ramp-up phase; EBITDA losses are near peak with steady improvement expected, but no specific breakeven guidance provided.
- →ARPOB growth is expected to moderate to single digits (5%-7% annually) in the next 2-3 years, lower than past double-digit growth.
- →CAPEX is projected around Rs. 1,000 crores next fiscal year, lower than previous year, mainly maintenance and margin improvement in Noida.
- →Mature hospitals expected to sustain margins in the 22%-25% range, with no significant structural changes.
- →Capacity expansions and new specialty additions (robotics, cancer care) are expected to drive volume and revenue growth.
- →Overall confidence expressed in sustainable value creation from current investments and ramp-up activities.
🏗️ Capital Expenditure Plans
- →Global Health Limited plans a CAPEX of approximately Rs. 1,000 crores for the next fiscal year (FY27), part of a broader Rs. 3,000 crores investment over five years.
- →The bulk of recent CAPEX was directed toward the Noida facility, with Rs. 600-700 crores spent last year.
- →FY27 CAPEX is expected to be lower than Rs. 1,000 crores, possibly below Rs. 500 crores, as many new projects are in early stages and major spending is back-ended 2-3 years out.
- →Incremental capital spending in older units will focus on maintenance and margin improvements, particularly in Noida.
- →Expansion includes adding beds across multiple locations: 99 at Patna, 110 at Ranchi, 328 at Noida in FY26; further additions possible through brownfield expansions at Lucknow (193 beds), Patna (81 beds), and Noida (222 beds).
- →Ongoing projects in Guwahati, Mumbai, South Delhi, and Pitampura are progressing through various approval and construction stages.
💰 Fundraising & Capital Structure
📋 Order Book & Pipeline
Key Metrics
Frequently Asked Questions
What were Global Health Ltd Q3 FY26 results?
Developing hospitals (Lucknow, Patna) are showing strong growth with income up 28% in 9 months (excluding Noida) and margin expansion from 30% to 31.1%. Developing hospitals like Lucknow and Patna are showing strong double-digit revenue and EBITDA growth, with Lucknow margins improving by over 150 bps YoY and stable Patna margins. - Medanta Noida is in ramp-up phase; EBITDA losses are near peak with steady improvement expected, but no specific breakeven guidance provided. - ARPOB growth is expected to moderate to single digits (5%-7% annually) in the next 2-3 years, lower than past double-digit growth. - CAPEX is projected around Rs.
What is Global Health Ltd share price analysis?
Global Health Ltd currently shows a neutral. The stock trades at a P/E of 66.2 with a market cap of ₹37,919 Cr. Investors should review the full earnings analysis for detailed insights.
Is Global Health Ltd planning capital expenditure?
Global Health Limited plans a CAPEX of approximately Rs.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.